Rival antiviral pills from Pfizer Inc. and Merck & Co. that demonstrated efficacy in trials of adults with COVID-19 who are at high risk of serious illness are now both in use. The drugs are being studied to see if they can prevent infection in people exposed to the virus.
Here is an explanation of the differences in the two pills.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.